Tealwood Asset Management Inc. increased its position in Amgen Inc. (NASDAQ:AMGN) by 2.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,088 shares of the medical research company’s stock after buying an additional 237 shares during the period. Tealwood Asset Management Inc.’s holdings in Amgen were worth $1,839,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Oakworth Capital Inc. increased its stake in shares of Amgen by 16.6% in the second quarter. Oakworth Capital Inc. now owns 701 shares of the medical research company’s stock worth $111,000 after buying an additional 100 shares in the last quarter. Delta Asset Management LLC TN increased its stake in shares of Amgen by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 1,020 shares of the medical research company’s stock worth $155,000 after buying an additional 85 shares in the last quarter. Capital Advisors Ltd. LLC increased its stake in shares of Amgen by 0.6% in the second quarter. Capital Advisors Ltd. LLC now owns 1,078 shares of the medical research company’s stock worth $164,000 after buying an additional 6 shares in the last quarter. Vigilant Capital Management LLC increased its stake in shares of Amgen by 2.6% in the second quarter. Vigilant Capital Management LLC now owns 1,283 shares of the medical research company’s stock worth $195,000 after buying an additional 33 shares in the last quarter. Finally, Calamos Wealth Management LLC acquired a new stake in shares of Amgen during the second quarter worth $202,000. 79.12% of the stock is currently owned by institutional investors and hedge funds.
Amgen Inc. (NASDAQ:AMGN) traded up 0.44% during trading on Monday, reaching $162.62. The company’s stock had a trading volume of 2,348,428 shares. The firm has a market cap of $121.70 billion, a PE ratio of 16.64 and a beta of 0.94. Amgen Inc. has a one year low of $139.02 and a one year high of $176.85. The company has a 50-day moving average of $169.32 and a 200 day moving average of $162.55.
Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, July 27th. The medical research company reported $2.84 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.74 by $0.10. The company earned $5.69 billion during the quarter, compared to analyst estimates of $5.58 billion. Amgen had a net margin of 33.07% and a return on equity of 29.30%. Amgen’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period in the prior year, the business posted $2.57 earnings per share. Analysts expect that Amgen Inc. will post $11.35 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 8th. Stockholders of record on Wednesday, November 16th will be issued a dividend of $1.00 per share. The ex-dividend date is Monday, November 14th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 2.46%. Amgen’s dividend payout ratio is currently 40.90%.
A number of equities research analysts have weighed in on the company. Jefferies Group raised their target price on Amgen from $187.00 to $198.00 and gave the company a “buy” rating in a report on Thursday, July 28th. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $166.00 target price on the stock in a report on Wednesday, June 29th. Citigroup Inc. reduced their target price on Amgen from $175.00 to $172.00 and set a “neutral” rating on the stock in a report on Wednesday, September 28th. Leerink Swann reaffirmed a “hold” rating on shares of Amgen in a report on Sunday, June 26th. Finally, Argus reaffirmed a “buy” rating and issued a $195.00 target price (up previously from $185.00) on shares of Amgen in a report on Friday, August 5th. One analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $184.94.
In other news, VP Annette Louise Such sold 3,000 shares of the stock in a transaction dated Tuesday, August 2nd. The shares were sold at an average price of $174.59, for a total transaction of $523,770.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.20% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company’s business segment is human therapeutics. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine).